Personalised approaches to treating GU cancers
November 27, 2021Read morePersonalised approaches such as the use of circulating tumour DNA (ctDNA) biomarkers and genetic testing is the way to...
00
Trial updates: NIMBUS, FLAME and IMvigor130
November 27, 2021Read morePresenters of Plenary Session 5 kickstarted day three of EMUC21 and delivered developments on the trials NIMBUS, Focal Lesion...
EMUC21 shines spotlight on best poster winners
November 27, 2021Read moreDemonstrating the multidisciplinary nature of the congress, an oncologist, a radiotherapist, and a urologist each received a Best Poster...
Bladder-preserving strategies unveiled: Topical therapy and TURBT
November 26, 2021Read moreIn order to preserve the quality of life for non-muscle-invasive bladder cancer (NMIBC) patients as much as possible, bladder-preserving...
Plenary Session 3: Promising biomarkers and novel approaches for patients with BCG failure
November 26, 2021Read morePresenter Prof. Paolo Gontero (IT) launched Plenary Session 3 “Bladder cancer: Bladder-preserving strategies in NMIBC” at EMUC21 today with...
PSMA PET/CT: Prime tool in staging and treatment monitoring
November 26, 2021Read morePlenary Session 1 “Prostate cancer staging in 2021: Where are we, where are we going?” provided delegates with expert...
Strengths and limitations of PSMA PET: When to use it (and when not to)
November 26, 2021Read moreThe prostate-specific membrane antigen positron emission tomography (PSMA PET) scan is the (relatively) new kid on the block in...
Expectations for new WHO classification and what’s next in PCa grading
November 25, 2021Read moreThe EMUC Symposium on Genitourinary Pathology and Molecular Diagnostics (ESUP) delivered updates and expert insights on topics such as...
Definitive: EMUC21 is coming to Athens!
September 24, 2021Read moreNew crucial updates in GU cancer prevention, diagnosis and management Relive and enjoy the congress experience, meet and connect...
